• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经激肽拮抗剂的研究。3. 新型支链三肽Nα-(取代的L-天冬氨酰基、L-鸟氨酰基或L-赖氨酰基)-N-甲基-N-(苯甲基)-L-苯丙氨酰胺作为P物质拮抗剂的设计与构效关系。

Studies on neurokinin antagonists. 3. Design and structure-activity relationships of new branched tripeptides N alpha-(substituted L-aspartyl, L-ornithyl, or L-lysyl)-N-methyl-N-(phenylmethyl)-L-phenylalaninamides as substance P antagonists.

作者信息

Hagiwara D, Miyake H, Murano K, Morimoto H, Murai M, Fujii T, Nakanishi I, Matsuo M

机构信息

New Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd. Osaka, Japan.

出版信息

J Med Chem. 1993 Aug 6;36(16):2266-78. doi: 10.1021/jm00068a003.

DOI:10.1021/jm00068a003
PMID:7689652
Abstract

As an extension of our study on discovering a novel substance P (SP) antagonist, we designed new branched tripeptides containing L-aspartic acid (2 and 5), L-ornithine (3 and 6), and L-lysine (4 and 7) by reconstructing the structure of the previously reported tripeptide SP antagonist [Ac-Thr-D-Trp(CHO)-Phe-NMeBzl (1), FR113680]. The strategy for this design was based on the postulate that the dipeptide half D-Trp(CHO)-Phe-NMeBzl in 1 is essential for receptor recognition. Molecular modeling studies implied that these newly designed tripeptides could mimic the spatial orientations of the essential dipeptide structure. As expected, all of these compounds potently inhibited 3H-SP (1 nM) binding to guinea pig lung membranes in the 10(-8) M range. The 1H-indol-3-ylcarbonyl derivatives (5-7) were slightly more potent than the corresponding 1H-indol-2-ylcarbonyl derivatives (2-4), as predicted by the molecular modeling studies. The structure-activity relationships studies on the selected 1H-indol-3-ylcarbonyl derivatives indicated that the threonine moiety at the side chain can be modified into a variety of structures without any significant loss of the activity. Furthermore in the L-lysine series, even dipeptide compounds having nothing or a simple acyl group at the epsilon-amino group, such as N alpha-[N alpha-(1H-indol-3-ylcarbonyl)-L-lysyl]-N-methyl-N-(phenylmethyl)- L-phenylalaninamide (18b), exhibited potent activity. These dipeptides belong to a new structural class of SP antagonist.

摘要

作为我们发现新型P物质(SP)拮抗剂研究的拓展,我们通过重构先前报道的三肽SP拮抗剂[Ac-Thr-D-Trp(CHO)-Phe-NMeBzl (1),FR113680]的结构,设计了含有L-天冬氨酸(2和5)、L-鸟氨酸(3和6)以及L-赖氨酸(4和7)的新型支链三肽。该设计策略基于这样的假设:1中的二肽半体D-Trp(CHO)-Phe-NMeBzl对于受体识别至关重要。分子模拟研究表明,这些新设计的三肽能够模拟必需二肽结构的空间取向。正如预期的那样,所有这些化合物在10(-8) M范围内均能有效抑制3H-SP(1 nM)与豚鼠肺膜的结合。如分子模拟研究所预测的,1H-吲哚-3-基羰基衍生物(5 - 7)的活性略高于相应的1H-吲哚-2-基羰基衍生物(2 - 4)。对所选1H-吲哚-3-基羰基衍生物的构效关系研究表明,侧链上的苏氨酸部分可以修饰成多种结构,而活性不会有任何显著损失。此外,在L-赖氨酸系列中,即使是在ε-氨基上没有或只有简单酰基的二肽化合物,如Nα-[Nα-(1H-吲哚-3-基羰基)-L-赖氨酰]-N-甲基-N-(苯甲基)-L-苯丙氨酰胺(18b),也表现出强效活性。这些二肽属于SP拮抗剂的一种新结构类别。

相似文献

1
Studies on neurokinin antagonists. 3. Design and structure-activity relationships of new branched tripeptides N alpha-(substituted L-aspartyl, L-ornithyl, or L-lysyl)-N-methyl-N-(phenylmethyl)-L-phenylalaninamides as substance P antagonists.神经激肽拮抗剂的研究。3. 新型支链三肽Nα-(取代的L-天冬氨酰基、L-鸟氨酰基或L-赖氨酰基)-N-甲基-N-(苯甲基)-L-苯丙氨酰胺作为P物质拮抗剂的设计与构效关系。
J Med Chem. 1993 Aug 6;36(16):2266-78. doi: 10.1021/jm00068a003.
2
Studies on neurokinin antagonists. 2. Design and structure-activity relationships of novel tripeptide substance P antagonists, N alpha-[N alpha-(N alpha-acetyl-L-threonyl)-N1-formyl-D-tryptophyl]-N- methyl-N-(phenylmethyl)-L-phenylalaninamide and its related compounds.神经激肽拮抗剂的研究。2. 新型三肽P物质拮抗剂Nα-[Nα-(Nα-乙酰基-L-苏氨酰基)-N1-甲酰基-D-色氨酰基]-N-甲基-N-(苯基甲基)-L-苯丙氨酰胺及其相关化合物的设计与构效关系
J Med Chem. 1992 Aug 21;35(17):3184-91. doi: 10.1021/jm00095a013.
3
Studies on neurokinin antagonists. 4. Synthesis and structure-activity relationships of novel dipeptide substance P antagonists: N2-[(4R)-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-prolyl]-N- methyl-N-(phenylmethyl)-3-(2-naphthyl)-L-alaninamide and its related compounds.神经激肽拮抗剂的研究。4. 新型二肽P物质拮抗剂的合成及构效关系:N2-[(4R)-4-羟基-1-[(1-甲基-1H-吲哚-3-基)羰基]-L-脯氨酰]-N-甲基-N-(苯甲基)-3-(2-萘基)-L-丙氨酰胺及其相关化合物
J Med Chem. 1994 Jun 24;37(13):2090-9. doi: 10.1021/jm00039a022.
4
Studies on neurokinin antagonists. 1. The design of novel tripeptides possessing the glutaminyl-D-tryptophylphenylalanine sequence as substance P antagonists.神经激肽拮抗剂的研究。1. 具有谷氨酰胺基-D-色氨酰苯丙氨酸序列作为P物质拮抗剂的新型三肽的设计。
J Med Chem. 1992 May 29;35(11):2015-25. doi: 10.1021/jm00089a011.
5
FR 113680: a novel tripeptide substance P antagonist with NK1 receptor selectivity.FR 113680:一种具有NK1受体选择性的新型三肽P物质拮抗剂。
Br J Pharmacol. 1992 May;106(1):123-6. doi: 10.1111/j.1476-5381.1992.tb14303.x.
6
Analogues of substance P. Peptides containing D-amino acid residues in various positions of substance P and displaying agonist or receptor selective antagonist effects.
J Med Chem. 1986 Jul;29(7):1163-71. doi: 10.1021/jm00157a008.
7
Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist.肽模拟物MEN 11149的药理学,一种新型强效、选择性且口服有效的速激肽NK1受体拮抗剂。
Eur J Pharmacol. 1998 Jan 12;341(2-3):201-9. doi: 10.1016/s0014-2999(97)01453-2.
8
FK 224, a novel cyclopeptide substance P antagonist with NK1 and NK2 receptor selectivity.FK 224,一种对NK1和NK2受体具有选择性的新型环肽物质P拮抗剂。
J Pharmacol Exp Ther. 1992 Jul;262(1):398-402.
9
Synthesis and substance P antagonist activity of naphthimidazolium derivatives.萘并咪唑鎓衍生物的合成及P物质拮抗剂活性
J Med Chem. 1992 Apr 3;35(7):1273-9. doi: 10.1021/jm00085a015.
10
Effects of the tripeptide substance P antagonist, FR113680, on airway constriction and airway edema induced by neurokinins in guinea-pigs.
Eur J Pharmacol. 1992 Jun 24;217(1):23-9. doi: 10.1016/0014-2999(92)90506-y.

引用本文的文献

1
Ascaroside activity in Caenorhabditis elegans is highly dependent on chemical structure.在秀丽隐杆线虫中,阿索糖苷的活性高度依赖于化学结构。
Bioorg Med Chem. 2013 Sep 15;21(18):5754-69. doi: 10.1016/j.bmc.2013.07.018. Epub 2013 Jul 18.